Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
07 nov. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD to conclude patient...
Axsome Therapeutics to Report Third Quarter 2019 Financial Results on November 7, 2019
29 oct. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, November 7, 2019 at 8:00 AM Eastern Time NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Announces Completion of Patient Enrollment in the GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
16 oct. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Provide Update on Continued Progress at the 2019 Cantor Global Healthcare Conference
02 oct. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD on track for readout of topline results in 4Q 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD on track for readout of topline results in 4Q...
Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
03 sept. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Appoints David Marek as Chief Commercial Officer
20 août 2019 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
08 août 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Both STRIDE-1 Phase 3 trial in TRD and GEMINI Phase 3 trial in MDD for AXS-05 on track for readout of topline results in 2H 2019 MOMENTUM Phase 3 trial of AXS-07 in migraine on track for readout of...
Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019
30 juil. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, August 8, 2019 at 8:00 AM Eastern Time NEW YORK, July 30, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility
29 juil. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Extends interest-only period and time to access additional funding NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company...
Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes
01 juil. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...